VCEL
Vericel·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Gap Down
Significant Net Income Growth
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VCEL
Vericel Corporation
A leader in advanced therapies for the sports medicine and severe burn care markets
64 Sidney Street, Cambridge, MA 02139
--
Founded in 1989, Vericel Corporation is a regenerative medicine company focused on the development of innovative cell therapies to repair or regenerate damaged or diseased tissue. The company is developing multicellular therapies for specific patients with severe, chronic ischemic cardiovascular and cerebrovascular diseases. The company believes that ixmyelocel-T is a multifunctional disease improvement therapy that includes tissue remodeling, immune regulation and promotion of angiogenesis. The company's proprietary battery manufacturing technology makes it possible to manufacture multicellular therapies that expand the bone marrow of adult patients and deliver them directly to damaged tissue. Preclinical and clinical data suggest that ixmyelocel-T may be safe and effective in the treatment of severe, chronic ischemic cardiovascular diseases such as severe limb ischemia (CLI), the most serious peripheral artery disease (PAD), and dilated cardiomyopathy (DCM), the third leading cause of heart failure.
Earnings Call
Q2/2025
Estimate EPS-0.04
Actual EPS-0.01
Estimate Revenue64.49M
Actual Revenue63.24M
Vericel's Q2 2025: Unpacking Contradictions in MACI Arthro Growth, Conversion Rates, and Margin Targets
Aug 02,2025 08:34
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
VCEL has released its 2025 Q3 earnings. EPS was reported at 0.1, versus the expected -0.01, beating expectations. The chart below visualizes how VCEL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VCEL has released its 2025 Q3 earnings report, with revenue of 67.50M, reflecting a YoY change of 16.58%, and net profit of 5.07M, showing a YoY change of 663.15%. The Sankey diagram below clearly presents VCEL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
